ABSTRACT
Objective: To investigate whether piperlongumine can sensitize prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and trigger apoptosis in prostate cells. Methods: Human prostate cancer cell lines PC3, LNCaP, and VCaP were cultured with piperlongumine and TRAIL. Then, cell proliferation, migration, caspase activation, apoptotic protein expressions, and death receptor expressions were measured. Results: Piperlongumine inhibited cell proliferation at low doses (<10 μM) alone and in combination with TRAIL (25 ng/mL), induced apoptosis, and suppressed cyclooxygenase activation. Additionally, piperlongumine induced expression of death receptors which potentiated TRAIL-induced apoptosis in cancer cells but did not affect decoy receptors. Piperlongumine also downregulated tumor cell-survival pathways, inhibited colony formation and migration of cancer cells alone or in combination with TRAIL. The combination of piperlongumine with TRAIL was found to be synergistic. Conclusions: Our findings indicate that piperlongumine can sensitize cancer cells to TRAIL through the upregulation of death receptors and can trigger apoptosis with the downregulation of anti-apoptotic proteins.
ABSTRACT
To establish whether the Ischemia-Modified Albumin [IMA], a new parameter of oxidative stress, has diagnostic role in experimental acute pancreatitis. Randomized controlled trial. Experimental Animal Center, Canakkale Onsekiz Mart University, Canakkale, Turkey, from May to September 2013. Sixteen Sprague-Dawley rats were randomly divided into two groups [n=8 each]: Sham and AP groups. AP was induced by ligation of pancreatic duct. Serum IMA, amylase, lipase, AST, ALT and CRP were determined. The severity of pancreatitis was scored by a blinded pathologist under microscope. Serum IMA levels in the AP group increased significantly compared with the control group [p < 0.05]. There was also a strong positive correlation between amylase and IMA levels. The present study showed in a rodent model that serum IMA might serve as an additional marker to monitor inflammation during pancreatitis
ABSTRACT
To investigate early diagnostic effects of serum myelin basic protein [MBP] and ischemic modified albumin [IMA] levels in patients with ischemic stroke. Fifty patients who presented to an emergency service with acute ischemic stroke between June 2013 to March 2014 were evaluated with the National Institute of Health Stroke Scale [NIHSS] and diffusion-weighted magnetic resonance imaging [MRI]. Thirty four healthy cases were included as control group. All patients serum IMA and MBP level were assessed. Mean IMA value was 0.52 +/- 0.25 cases with acute ischemic stroke and serum IMA levels were significantly higher than the control group [p<0.01]. No statistical significance was observed between acute ischemic stroke group and control group related to the MBP serum levels [P>0.05]. Statistically significant correlation was detected between the volumes of diffusion restri0:ion on MRI and NIHSS score [P=0.002,r=0.43] and IMA [P=0.015,r=0.344] levels. We have found that serum IMA levels are elevated in acute ischemic stroke cases and these levels are correlated with the ischemic tissue volume. MBP levels do not increase in early period of stroke cases